Tag Archives: Merck & Co

Merck Shows Off Bevy of New Drugs

By George Koroneos | Published: May 6, 2010
Image by Chemical Heritage Foundation via Flickr While Merck’s net profits might be a little low in the wake of the Schering-Plough merger, it’s pipeline—and future sales—are far from bleak. According to a new report from analyst firm Deutsche Bank, Merck has no less than 18 drugs in Phase III development, with three slated for launch within [...]
Posted in R&D, Strategy | Also tagged , , , , , | Leave a comment

A Few Words About Diversification

By Julian Upton | Published: February 1, 2010
Guest blog by Dr Brian White, an analyst at Shore Capital. As a result of the feared impact of the patent expiry cliff, the decimation of branded sales by multi-sourced generics and the obstacles erected, especially by managed care in the US, to slow the uptake of branded pharmaceuticals where a generic in the same class [...]
Posted in Europe, Global, Guest Blog, Strategy | Also tagged , , , , , | Leave a comment

Merck, Schering-Plough Merger Boosts Global Profile, but Questions Linger

By Andrew Sheivachman | Published: November 5, 2009
Image via Wikipedia After Merck & Co. officially announced its $41.1 billion merger with Schering-Plough yesterday, CEO Richard Clark made it clear his company is still looking to expand through further acquisitions and mergers. According to the Wall Street Journal’s Health Blog: Clark told us today that the newly combined company  is “actively looking” for biotechs to [...]
Posted in Strategy | Also tagged , , , , , , | 2 Comments